BPC-157 Dosage: How Much to Take, When & How

BPC-157 Dosage: How Much to Take, When & How

Disclaimer: This guide is educational content for informational purposes only and should not be construed as medical advice. BPC-157 is not approved by the FDA or EMA for human use. Consult with a qualified healthcare provider before using any novel compounds, especially if you have underlying health conditions, are taking medications, or have a personal or family history of cancer. This information is based on available research, animal studies, and biohacking community reports—human clinical trial data remains limited.

Overview

BPC-157 (Body Protection Compound 157) is a 15-amino acid synthetic peptide derived from human gastric juice protein. In research and biohacking communities, it is valued for its tissue-healing, regenerative, and neuroprotective properties. The compound is available via two primary administration routes: injection and oral. Understanding proper dosing is critical for safety and efficacy, as dosage varies significantly by route of administration and intended use.

The standard dosing ranges are:

• Injection: 250–500 mcg once daily
• Oral: 500–1,000 mcg once daily

This guide covers practical dosing protocols to help users make informed decisions about administration.

Standard Dosing Protocol

BPC-157 dosing differs substantially based on the administration route, as oral bioavailability is lower than parenteral delivery.

Injected Administration (Subcutaneous or Intramuscular)

Standard dose: 250–500 mcg once daily

The most commonly cited dosing protocol in biohacking communities falls at the lower end of this range (250–300 mcg) for general tissue repair and injury recovery. This dose is administered via subcutaneous or intramuscular injection, typically into the abdomen, thigh, or upper arm.

• Minimum effective dose: 250 mcg (250 micrograms)
• Standard dose: 250–350 mcg
• Higher dose: 400–500 mcg (used when faster healing is desired or for severe injuries)

Injection provides the highest bioavailability and most direct systemic distribution. Most users report effects beginning within 3–7 days of consistent dosing.

Oral Administration

Standard dose: 500–1,000 mcg once daily

Oral BPC-157 requires higher doses due to lower absorption rates. The typical starting protocol is 500–750 mcg taken once daily, often with food. Some users progress to 1,000 mcg daily after 1–2 weeks.

Oral dosing is preferred by users who are needle-averse or seeking systemic gut-healing benefits, as the peptide passes through the gastrointestinal tract before absorption. Effects typically appear within 7–14 days.

Dosing by Goal

BPC-157's versatility means dosing strategies vary depending on primary use case. Below are goal-specific protocols based on available research and community experience.

Injury Recovery & Tissue Healing

Injected: 250–350 mcg daily (lower end for mild-to-moderate injury; 400–500 mcg for severe injury)
Oral: 750–1,000 mcg daily
Duration: 8–12 weeks

This is the most researched application. Animal studies demonstrate significant acceleration of tendon, ligament, and muscle repair. Users with acute injuries (torn ligaments, muscle strains, tendon injuries) typically start at the lower injection dose and remain consistent daily.

Gut Healing & Leaky Gut

Injected: 250–300 mcg daily
Oral: 500–750 mcg daily (preferred route for direct GI tract contact)
Duration: 12–16 weeks

Oral administration is particularly popular for gut-related applications because the peptide traverses the intestinal epithelium. Users with inflammatory bowel disease or suspected leaky gut often favor oral dosing to maximize local gastrointestinal effects.

Joint Health & Cartilage Support

Injected: 250–400 mcg daily (some protocols include intra-articular injection for localized delivery)
Oral: 500–1,000 mcg daily
Duration: 12–16 weeks

Joint applications have limited human data but promising preliminary reports. Higher doses may be warranted for degenerative joint conditions. Some advanced users combine systemic injection with localized intra-articular delivery under professional supervision.

Neuroprotection & Cognitive Recovery

Injected: 250–350 mcg daily
Oral: 500–1,000 mcg daily
Duration: 8–12 weeks

Animal studies suggest BPC-157 provides neuroprotective benefits and supports memory recovery. Dosing for cognitive applications mirrors that of injury recovery, as the mechanisms overlap (growth hormone receptor upregulation, angiogenesis, cytoprotective protein expression).

How to Administer

Injection Technique

Subcutaneous injection is the most practical route for self-administration:

1. Reconstitution: If purchasing lyophilized (freeze-dried) BPC-157, reconstitute with bacteriostatic water according to supplier instructions, typically yielding a solution of 250–500 mcg/mL.
2. Site selection: Rotate injection sites—abdomen, upper thigh, upper arm, or buttocks. Rotating prevents lipodystrophy and reduces local irritation.
3. Administration: Use a 27–31 gauge insulin syringe. Pinch the skin, insert the needle at a 45–90-degree angle, and slowly inject. Aspiration (pulling back on the plunger) is optional for subcutaneous injections.
4. Timing: Administer at the same time daily for consistency. Many users inject in the morning.
5. Storage: Store reconstituted solutions in a refrigerator (2–8°C) for up to 30 days. Some protocols recommend adding bacteriostatic water to the vial to maintain sterility.

Expected injection site effects: Mild redness, swelling, or bruising at the injection site is normal and typically resolves within 24 hours.

Oral Administration

1. Dosing form: BPC-157 is available as a powder capsule or as a liquid solution. Capsule dosing is straightforward; liquids can be dosed sublingually or swallowed.
2. Timing: Take once daily with or without food, though some users report better absorption when taken with a meal containing fat.
3. Consistency: Oral administration requires daily adherence for effects to manifest; missing doses delays benefits.
4. Storage: Keep oral forms in a cool, dry place away from light and heat. Properly stored, shelf stability is typically 12–24 months.

Cycling & Timing

Recommended Cycle Structure

Most users follow a 12-week on, 4-week off cycle for injury recovery and tissue healing applications:

• Weeks 1–12: Daily dosing (250–500 mcg injected or 500–1,000 mcg oral)
• Weeks 13–16: Off-cycle (no BPC-157)
• Repeat or adjust based on recovery progress and symptoms

This structure allows the body's endogenous repair mechanisms to re-engage while preventing potential tolerance or receptor desensitization.

Extended Protocols

For chronic conditions (leaky gut, joint degeneration, neuropathic issues), some users employ continuous 16-week cycles followed by a 4–6-week break. Evidence supporting optimal cycling is limited, so consistency and monitoring are critical.

Timing Considerations

• Injection timing: Morning injection allows users to monitor for side effects (dizziness, nausea) during the day.
• Oral timing: Evening dosing is sometimes preferred to avoid nausea or GI discomfort during work or exercise.
• Training: Users engaged in heavy resistance training often time higher BPC-157 doses (400–500 mcg) around training days, though consistent daily dosing appears to be the primary driver of benefit.

Beginner vs Advanced Dosing

Beginner Protocol

• Route: Oral (fewer barrier to entry, no injection training required)
• Dose: 500 mcg once daily
• Duration: 12 weeks
• Goal: General tissue healing, injury recovery
• Monitoring: Track symptom improvement weekly; adjust to 750 mcg at week 3–4 if well-tolerated

Beginners should start at the lower end of dosing ranges to assess tolerance. Nausea and mild GI discomfort are the most common side effects at higher oral doses.

Intermediate Protocol

• Route: Injection (subcutaneous)
• Dose: 250 mcg daily weeks 1–4; increase to 300–350 mcg weeks 5–12
• Duration: 12 weeks on, 4 weeks off
• Goal: Faster tissue recovery, specific injury repair
• Monitoring: Assess injection site reactions; track functional improvement (range of motion, pain reduction)

Intermediate users typically migrate to injection for faster results and lower total compound cost.

Advanced Protocol

• Route: Combination (injection + targeted intra-articular or localized injections)
• Dose: 300–500 mcg daily systemic + localized intra-articular (50–250 mcg) for joint applications
• Duration: 16 weeks on, 6 weeks off (extended cycle for chronic conditions)
• Goal: Maximal tissue regeneration, complex injury recovery, multi-site repair
• Monitoring: Regular functional assessments; consider professional administration for intra-articular injections

Advanced protocols are typically pursued under professional guidance and are reserved for serious injuries or chronic conditions.

Common Dosing Mistakes

1. Exceeding Maximum Daily Doses

Doses above 500 mcg injected or 1,200 mcg oral provide no additional benefit in available studies and increase side effect risk. More is not better with BPC-157.

2. Inconsistent Dosing Schedule

Missing doses or irregular dosing significantly delays benefits. BPC-157 requires consistent daily administration for optimal results. Users skipping doses report slower healing timelines.

3. Switching Routes Mid-Cycle

Changing from oral to injection or vice versa mid-protocol complicates outcome tracking. Maintain the same route for an entire 12-week cycle before switching.

4. Insufficient Cycle Duration

Benefit onset typically requires 7–14 days for observable effects. Terminating use before 8 weeks significantly reduces efficacy. Most protocols require 12+ weeks for full benefits to manifest.

5. Inadequate Reconstitution or Dilution

Improperly reconstituted injection solutions (incorrect water volume, contamination, improper storage) reduce potency. Always use bacteriostatic water, sterile technique, and proper refrigeration.

6. Ignoring Individual Tolerance

Side effects vary. Users experiencing persistent nausea on 1,000 mcg oral should reduce to 750 mcg or switch to injection. Tolerance is individual—adjust protocols accordingly.

7. Combining Multiple Peptides Without Protocol Adjustment

Stacking BPC-157 with other peptides (TB-500, AOD-9604, etc.) without dosage adjustment may increase side effects. If combining compounds, consider reducing BPC-157 to the lower end of dosing ranges.

Cost-Effectiveness Analysis

Typical cost: $40–$120 per month

Cost Breakdown by Route

Injection (subcutaneous):

• 250 mcg daily = 7,500 mcg monthly
• Cost per dose: $0.05–$0.15
• Monthly cost: $40–$70

Oral:

• 500–750 mcg daily = 15,000–22,500 mcg monthly
• Cost per dose: $0.10–$0.25
• Monthly cost: $60–$120

Injection is typically more cost-effective on a per-dose basis, especially when buying in bulk and maintaining a 12-week cycle. The upfront investment in sterile supplies and reconstitution materials is offset by lower per-dose costs over time.

Summary Dosing Table

Final Recommendations

BPC-157 dosing should be consistent, conservative, and monitored. Start at the lower end of dosing ranges—250 mcg injected or 500 mcg oral—and increase only if needed after 3–4 weeks of use. Track progress objectively (pain levels, functional range of motion, symptom resolution) rather than adjusting doses based on subjective feelings alone.

Combine dosing protocols with supportive practices: adequate sleep, protein intake, hydration, and controlled stress during the healing window. BPC-157 accelerates tissue repair but does not replace these foundational recovery components.

Finally, purchase from reputable suppliers, verify product purity if possible, and maintain sterile technique with injected forms. Poor-quality or contaminated BPC-157 compromises safety and efficacy.